In Vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3220-3225

  Wiskirchen, Dora E ^a   Crandon, Jared L ^a   Furtado, Guilherme H ^a   Williams, Gregory ^b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b Cerexa Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; CEFTAROLINE; EXTENDED SPECTRUM BETA LACTAMASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; FEMALE; HOST; IMMUNE STATUS; IMMUNOCOMPETENCE; IN VIVO STUDY; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SIMULATION;

ANIMALS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CEPHALOSPORINS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; THIGH;

EID: 79959280244     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00024-11     Document Type: Article

References (21)

1. Ambrose, P. G., et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
2. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
3. Andes, D., and W. A. Craig. 2006. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50:1376-1383.
4. DeRyke, C. A., S. Y. Lee, J. L. Kuti, and D. P. Nicolau. 2006. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles. Drugs 66:1-14.
5. Drusano, G. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
6. Drusano, G. L. 2010. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. J. Antimicrob. Chemother. 65(Suppl. 4):iv33-iv39.
7. Endimiani, A., Y. Choudhary, and R. A. Bonomo. 2009. In vitro activity of NXL104 in combination with β-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
8. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
9. Ishikawa, T., et al. 2003. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physiochemical and pharmacological properties. Bioorg. Med. Chem. 11:2427-2437.
10. Lautenbach, E., and R. Polk. 2007. Resistant gram-negative bacilli: a neglected healthcare crisis? Am. J. Health Syst. Pharm. 64:S3-S21.
11. Levasseur, P., et al. 2009. In vivo antibacterial efficacy of ceftaroline combined with the β-lactamase inhibitor NXL 104 in a murine septicemia model, abstract B-1339a. Abstr. 49th Annu. Meet. Intersci. Conf. Antimicrob. Agents Chemother.
12. Livermore, D. M., S. Mushtaq, M. Warner, C. Miossec, and N. Woodford. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
13. Lodise, P., B. M. Lomaestro, and G. L. Drusano. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 26:1320-1332.
14. Mushtaq, S., and D. M. Livermore. 2010. AmpC induction by ceftaroline. J. Antimicrob. Chemother. 65:586-588.
15. Mushtaq, S., M. Warner, G. Williams, I. Critchley, and D. M. Livermore. 2010. Activity of chequerboard combinations of ceftaroline and NXL 104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432.
16. Mushtaq, S., M. Warner, G. Yigong, K. Kaniga, and D. M. Livermore. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311.
17. National Nosocomial Infections Surveillance System. 2004. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32:470-485.
18. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
19. Sader, H. S., T. R. Fritsche, K. Kaniga, Y. Ge, and R. N. Jones. 2005. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49:3501-3512.
20. Stachyra, T., et al. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329.
21. Turnidge, J. D. 1998. The pharmacodynamics of β-lactams. Clin. Infect. Dis. 27:10-22.